Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

An investigational drug from Veru helped preserve lean mass in patients taking Wegovy, though some experts raised questions ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Patients taking the highest dose of amycretin experienced a mean weight ... And based on the data so far, amycretin looks even more impressive than Wegovy and Eli Lilly's Zepbound, the two top ...

CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.

LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday ...